Interventional Radiology Imaging

How Should You Manage Chronic VTE and Thromboembolic Pulmonary Hypertension?

·
How Should You Manage Chronic VTE and Thromboembolic Pulmonary Hypertension?

A 62-year-old patient with a history of recurrent deep vein thrombosis (DVT) presents to your clinic with six months of progressive dyspnea on exertion and new lower extremity edema. An echocardiogram reveals signs of right ventricular pressure overload. You suspect the long-term sequela of their venous thromboembolism (VTE) has evolved into chronic thromboembolic pulmonary hypertension (CTEPH). As you consider the complex management pathway, you question the role of an inferior vena cava (IVC) filter versus other interventions. This article provides a focused clinical workflow for this exact scenario, guiding you through the management options.

According to the American College of Radiology (ACR) Appropriateness Criteria, lifelong anticoagulation is the foundational management strategy and is rated Usually Appropriate for patients with chronic venous thromboembolism.

Who Fits This Clinical Scenario?

This guidance applies to patients with established chronic venous thromboembolism, particularly those who have developed the serious complication of chronic thromboembolic pulmonary hypertension (CTEPH). These individuals typically have a known history of acute pulmonary embolism (PE) or DVT, often months or years prior. The defining feature is the persistence of symptoms like dyspnea, fatigue, or signs of right heart failure well after the acute event, caused by organized, non-resolving thrombi in the pulmonary arteries.

This workflow is distinct from several related clinical situations:

  • Acute VTE: This guidance is not for patients with a new-onset DVT or PE. The management of acute VTE with a contraindication to anticoagulation involves different considerations, often prioritizing immediate filter placement.
  • VTE Prophylaxis: This scenario does not cover the prophylactic use of IVC filters in high-risk patients (e.g., major trauma) without a diagnosed VTE.
  • Filter Retrieval: This article does not address the routine follow-up and decision-making for retrieving an existing IVC filter once the initial indication has resolved.

The key differentiator is the chronicity of the disease process and the presence of secondary pulmonary hypertension, which shifts the focus from acute clot prevention to managing a complex vascular and cardiopulmonary condition.

What Diagnoses Are You Working Up in This Scenario?

In this clinical context, the primary diagnosis of chronic VTE is often already established. The “workup” is focused on confirming and characterizing its most severe complication, CTEPH, and assessing the patient for definitive treatment. The management plan hinges on understanding the extent and accessibility of the chronic thrombus.

Chronic Thromboembolic Pulmonary Hypertension (CTEPH): This is the central diagnosis. Unlike acute PE where the clot is fresh, CTEPH involves organized, fibrotic material that becomes incorporated into the walls of the pulmonary arteries. This process narrows and obstructs the vessels, progressively increasing pulmonary vascular resistance. The resulting pulmonary hypertension leads to right ventricular strain, hypertrophy, and eventual failure. Confirming CTEPH and assessing its hemodynamic severity is the main goal.

Recurrent Acute or Subacute VTE: A key consideration is whether the patient is experiencing a new, acute-on-chronic event. Patients with CTEPH are at high risk for further VTE. Differentiating new, reversible clot from chronic, organized material is critical for management, as acute events may require more aggressive anticoagulation or thrombolysis, while chronic disease requires evaluation for surgical intervention.

Right Heart Failure: The clinical presentation of dyspnea, edema, and fatigue is driven by the failing right ventricle. The workup aims to quantify the degree of right ventricular dysfunction and the severity of tricuspid regurgitation. This assessment is vital for risk stratification and determining the urgency of intervention.

Why Anticoagulation Is the Recommended Foundational Therapy

For patients with chronic VTE and CTEPH, the ACR Appropriateness Criteria designate both Anticoagulation and Pulmonary Thromboendarterectomy (PTE) as Usually Appropriate. This reflects a dual approach: lifelong medical therapy to prevent new clots, combined with evaluation for a potentially curative surgical procedure.

Anticoagulation is the cornerstone of management for all CTEPH patients, regardless of whether they are surgical candidates. It is essential for preventing the formation of new thrombi and the propagation of existing clots, both in the pulmonary arteries and the deep veins of the legs. This therapy mitigates the risk of superimposed acute events that could cause rapid clinical deterioration.

Pulmonary thromboendarterectomy is a complex surgical procedure to remove the organized, chronic thrombus from the pulmonary arteries. For patients with surgically accessible disease, PTE is the treatment of choice as it can be curative, leading to normalization of pulmonary hemodynamics and significant improvement in symptoms and long-term survival. A comprehensive evaluation at a specialized CTEPH center is required to determine surgical candidacy.

In contrast, other interventions are reserved for specific circumstances:

  • Permanent and Retrievable IVC Filters: Both are rated May be Appropriate. An IVC filter is not a primary treatment for CTEPH. Its role is adjunctive, considered for patients who have recurrent VTE despite adequate anticoagulation or for those who develop a contraindication to anticoagulation. It serves to prevent further clot embolization to the already compromised pulmonary circulation but does not address the underlying obstructive disease.
  • Balloon Pulmonary Angioplasty (BPA): This intervention is also rated May be Appropriate. BPA is a catheter-based procedure to improve blood flow in the smaller, more distal pulmonary arteries. It is a critical option for patients who are not candidates for PTE or who have persistent or recurrent pulmonary hypertension after surgery.

The management strategies in this ACR topic do not involve diagnostic imaging and therefore do not have associated radiation levels. The decision-making process is clinical and procedural, guided by prior imaging studies like V/Q scans, CT pulmonary angiography, and invasive right heart catheterization.

What’s Next After Diagnosis? Downstream Workflow

Once a diagnosis of CTEPH is confirmed and the patient is established on lifelong anticoagulation, the clinical pathway centers on determining eligibility for definitive therapy. This requires a multidisciplinary evaluation at an expert center.

  • If CTEPH is confirmed: The immediate next step is referral to a specialized pulmonary hypertension center with expertise in CTEPH. This is not a condition that should be managed in a general cardiology or pulmonology practice alone.
  • Evaluation for Operability: The expert center will perform a comprehensive assessment, including ventilation/perfusion (V/Q) scanning, high-resolution CT pulmonary angiography (CTPA), and right heart catheterization with pulmonary angiography. This workup determines if the chronic thrombus is surgically accessible.
  • If the patient is a candidate for PTE: The patient should proceed with pulmonary thromboendarterectomy. This offers the best chance for a cure and long-term survival.
  • If the patient is NOT a candidate for PTE: For patients with surgically inaccessible (e.g., very distal) disease or prohibitive surgical risk, the next steps involve advanced medical therapy with pulmonary hypertension-specific drugs and/or referral for Balloon Pulmonary Angioplasty (BPA).
  • If recurrent VTE occurs on therapy: If a patient develops a new DVT or PE while on therapeutic anticoagulation, an evaluation for an IVC filter is warranted. This is a key indication where a filter, rated May be Appropriate, enters the workflow.

Pitfalls to Avoid (and When to Get Help)

Navigating the management of CTEPH requires careful consideration to avoid common errors that can delay effective treatment and worsen outcomes.

  • Misattributing symptoms: A frequent pitfall is attributing a patient’s progressive dyspnea to other causes like COPD, asthma, or deconditioning, thereby delaying the diagnosis of CTEPH.
  • Delaying referral: CTEPH is a complex and relatively rare disease. Management, particularly the decision regarding operability for PTE, must be done at a specialized center. Delaying this referral can lead to irreversible right heart failure.
  • Inappropriate IVC filter placement: Placing an IVC filter as a primary or sole therapy for CTEPH is a significant error. Filters do not treat the established obstruction and should be reserved for specific indications like recurrent VTE on anticoagulation.
  • Failing to ensure lifelong anticoagulation: Unless a strong contraindication exists, all patients with CTEPH require lifelong anticoagulation, even after a successful PTE or BPA.

If CTEPH is suspected based on imaging and clinical history, immediate escalation to a dedicated pulmonary hypertension program is the most critical next step.

Related ACR Topics and Tools

For further reading and to explore adjacent clinical scenarios, the following resources provide authoritative guidance. The ACR Appropriateness Criteria are designed to help clinicians choose the right test for the right patient at the right time, and these tools can support that decision-making process.

Frequently Asked Questions

Is an IVC filter a standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH)?

No, an IVC filter is not a standard or primary treatment for CTEPH. According to the ACR, both permanent and retrievable IVC filters are rated ‘May be Appropriate’. Their use is reserved for adjunctive therapy in specific situations, such as patients who experience recurrent venous thromboembolism despite being on therapeutic anticoagulation, or for those who develop an absolute contraindication to anticoagulation.

Why is pulmonary thromboendarterectomy (PTE) also rated ‘Usually Appropriate’ alongside anticoagulation?

Anticoagulation and PTE address different aspects of the disease. Anticoagulation is a lifelong medical therapy to prevent new clot formation and is foundational for all CTEPH patients. PTE is a potentially curative surgical procedure that removes the organized, obstructive thrombus from the pulmonary arteries. For eligible candidates, PTE can normalize hemodynamics and reverse right heart failure. Therefore, both are considered ‘Usually Appropriate’ as key components of a comprehensive management strategy.

What is the role of Balloon Pulmonary Angioplasty (BPA) in managing CTEPH?

Balloon Pulmonary Angioplasty (BPA) is a catheter-based intervention rated ‘May be Appropriate’. It is a primary treatment option for patients with CTEPH who are not candidates for surgical PTE due to distal, inaccessible disease or prohibitive surgical risk. It can also be used to treat residual pulmonary hypertension in patients who have already undergone PTE.

If a patient with CTEPH is stable on anticoagulation, do they still need to be evaluated at a specialty center?

Yes, absolutely. All patients with a confirmed or suspected diagnosis of CTEPH should be referred to a specialized center with expertise in pulmonary hypertension and PTE surgery. This evaluation is critical to determine if the patient is a candidate for a potentially curative surgery (PTE) or other advanced therapies like BPA. Managing CTEPH with anticoagulation alone is insufficient if the patient is a candidate for definitive intervention.

Does this guidance apply to a patient with an old DVT but no symptoms of pulmonary hypertension?

This specific guidance is tailored to patients with chronic VTE who have developed symptomatic pulmonary hypertension (CTEPH). While a patient with a history of chronic DVT without pulmonary hypertension still requires management (typically long-term anticoagulation), the complex decision-making involving PTE, BPA, and adjunctive IVC filters is primarily relevant to the CTEPH population.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026